NS Pharma Begins Rolling NDA Submission to FDA for Viltolarsen (NS-065/NCNP-01)
PPMD is pleased to learn that NS Pharma has initiated submission of a rolling New Drug Application (NDA) seeking accelerated approval for viltolarsen (NS-065/NCNP-01), an investigational drug for the treatment of Duchenne in patients amenable…Learn More